Education
About Us
Working with TipRanks
Follow Us
Ryvu Therapeutics SA (DE:9Y4)
FRANKFURT:9Y4
9Y4 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.17 - €12.12
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€145.76M
Enterprise Value€657.21M
Total Cash (Recent Filing)€174.01M
Total Debt (Recent Filing)€74.23M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Nov 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding23,120,148
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.33Price Target Upside-0.31% Downside
Rating ConsensusHold
Number of Analyst Covering0
9Y4 FAQ
What was Ryvu Therapeutics SA’s price range in the past 12 months?
Ryvu Therapeutics SA lowest stock price was €4.17 and its highest was €12.12 in the past 12 months.
What is Ryvu Therapeutics SA’s market cap?
Ryvu Therapeutics SA’s market cap is €145.76M.
When is Ryvu Therapeutics SA’s upcoming earnings report date?
Ryvu Therapeutics SA’s upcoming earnings report date is Nov 20, 2025 which is in 51 days.
How were Ryvu Therapeutics SA’s earnings last quarter?
Ryvu Therapeutics SA released its earnings results on Sep 11, 2025. The company reported -€0.342 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.342.
Is Ryvu Therapeutics SA overvalued?
According to Wall Street analysts Ryvu Therapeutics SA’s price is currently Overvalued.
Does Ryvu Therapeutics SA pay dividends?
Ryvu Therapeutics SA does not currently pay dividends.
What is Ryvu Therapeutics SA’s EPS estimate?
Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ryvu Therapeutics SA have?
Ryvu Therapeutics SA has 23,120,148 shares outstanding.
What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?
Ryvu Therapeutics SA reported an EPS of -€0.342 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.614%.
Which hedge fund is a major shareholder of Ryvu Therapeutics SA?
Currently, no hedge funds are holding shares in DE:9Y4
Company Description
Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Technical Analysis
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―
Selvita SA
―
Mabion SA
―
Options Prices
Currently, No data available
---